Drug Trial Radar · NCT05396339
A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors.
Last checked: Nov 19, 2026Latest source record: Jul 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
120
Planned (sponsor's estimate)
Start
Jun 24, 2022
Primary completion
May 30, 2024
Study completion Nov 30, 2024
Sponsor
- Lead sponsor
- SUNHO(China)BioPharmaceutical CO., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 31, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I/IIa Clinical Trial to Evaluate the Safety,Tolerability,Pharmacokinetics and Preliminary Effectiveness of IAE0972 in Patients With Advanced Malignant Solid Tumors.
Conditions
- Advanced Malignant Solid Tumor
Interventions
IAE0972Drug
IAE0972 is an investigational product
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability of IAE0972 in Phase ITime frame: 28 days after last medication, an average of 1 year
- Objective response rate (ORR) in Phase IIaTime frame: Baeline until disease progression, assessed up to 36 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Affilated Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China · Not yet recruiting
Shanghai East Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.